Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of Sunday, August 30, 2026.
PE RATIO
N/A
Market Cap
$5.40B
PE Ratio
37.39
TTM Avg
37.42
3Y Avg
43.38
5Y Avg
55.10
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| PDS Biotechnology Corporation (PDSB) | $11.79M | N/A | N/A | N/A | N/A |
| Shoulder Innovations, Inc. (SI)vs › | $438.82M | N/A | N/A | N/A | N/A |
| NRC Health (NRC)vs › | $492.43M | 86.57 | 35.44 | 26.86 | 28.14 |
| Teladoc Health, Inc. (TDOC)vs › | $1.18B | N/A | N/A | N/A | N/A |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $2.23B | N/A | 23.81 | 50.79 | 57.43 |
| TransMedics Group, Inc. (TMDX)vs › | $3.06B | 22.91 | 37.40 | 494.99 | 494.99 |
| Doximity, Inc. (DOCS)vs › | $5.00B | 31.45 | 32.56 | 43.79 | 74.74 |
| Merit Medical Systems, Inc. (MMSI)vs › | $5.40B | 37.39 | 37.42 | 43.38 | 55.10 |
| Hims & Hers Health, Inc. (HIMS)vs › | $6.43B | N/A | 61.96 | 88.48 | 88.48 |
| Chemed Corporation (CHE)vs › | $6.84B | 26.27 | 23.62 | 28.18 | 28.43 |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$0.21
Forward EPS (Est.)
$-0.45
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
